Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
复制标题
DOI：
10.1007/s10067-011-1823-1
复制
发表时间：
2011-11-01
影响因子：
3.4
通讯作者：
Vilardell-Tarres, Miquel
中科院分区：
文献类型：
--
作者：
Pilar Simeon-Aznar, Carmen;Fonollosa-Pla, Vicent;Vilardell-Tarres, Miquel
本研究旨在确定霉酚酸钠（MS）在硬皮病（SSc）相关间质性肺病（ILD）患者中的有效性。在一项前瞻性观察性研究中，我们评价了14例连续接受MS治疗12个月的SSc-ILD患者。采用纵向数据分析方法研究代谢综合征对肺功能的影响。肺功能测定采用Wilcoxon秩和检验法测定用力肺活量（FVC）、1秒用力呼气量（FEV 1）和肺一氧化碳弥散量（DLCO）。作为一个组，在MS治疗12个月后，FVC、FEV 1和DLCO的中位值没有显著变化，符合美国胸科学会对疾病稳定的定义。个体而言，治疗12个月后，14例患者中有6例显示肺部改善，定义为FVC增加10%以上，14例患者中有5例保持稳定。相比之下，中位FVC较MS开始前12个月下降了7.2%，但不显著。未发现明显的药物不良反应。这些前瞻性数据表明，MS是SSc-ILD患者安全且耐受性良好的治疗方法，能够预防肺功能恶化。
This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational study, we evaluated 14 consecutive SSc-ILD patients who were treated with MS for 12 months. The effect of MS on lung function was examined by using longitudinal data analytic methods. Wilcoxon rank-sum tests were used to examine the forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) by pulmonary function testing. As a group, the median values for FVC, FEV1 and DLCO did not change significantly after 12 months of MS therapy and fulfilled the definition of stable disease by the American Thoracic Society. Individually, after 12 months of treatment, 6 out of 14 patients showed a pulmonary improvement defined as an increase of more than 10% in FVC, and 5 out of 14 patients remained stable. By contrast, the median FVC had declined a non-significant 7.2% from the previous 12 months before MS initiation. No significant drug adverse effects were registered. These prospective data suggest that MS is a safe and well-tolerated therapy for SSc-ILD patients, and it is capable of preventing functional pulmonary deterioration.